Pilot Study of RR-HNK in OCD
Key facts
- Who runs it
- Carolyn Rodriguez
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 45 people, planned
- Started
- 23 Jan 2026
- Expected to end
- 30 Nov 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- RR-HNK/Hydroxynorketamine
- Placebo
- Record updated
- 12 August 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Ages 18-65
- Meet the criteria for OCD diagnosis
- Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons
- Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures
- Able to provide informed consent
Who cannot take part
- Allergy or hypersensitivity to ketamine
- Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
- Lifetime history of deep brain stimulation
- Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Stanford University, School of MedicinePalo Alto, United StatesContact: Daniel Bello, BSTaking people
About the trial
What the trial wants to find out
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
The 3 groups in the trial
- 0.25 mg/kg RR-HNKTreatment being tested
OCD patients in this arm will receive 0.25mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
Treatment: RR-HNK/Hydroxynorketamine
- 0.5 mg/kg RR-HNKTreatment being tested
OCD patients in this arm will receive 0.5mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
Treatment: RR-HNK/Hydroxynorketamine
- Placebo (Sterile Saline)Placebo, for comparison
OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder
- Fit questions
- Built from NCT06575075, who can take part
- Record updated
- 12 August 2026